Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
3billion | RCV001775392 | SCV002012247 | likely pathogenic | Pyruvate dehydrogenase E1-alpha deficiency | 2021-10-02 | criteria provided, single submitter | clinical testing | The missense variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported (PM1). It is not observed in the gnomAD v2.1.1 dataset (PM2). The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.943, 3Cnet: 0.974, PP3). Patient's phenotype is considered compatible with Pyruvate Dehydrogenase E1-Alpha Dedicienct (3billion dataset, PP4). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline |
Clinical Genetics Laboratory, |
RCV004697139 | SCV005197118 | pathogenic | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV004697139 | SCV005627043 | pathogenic | not provided | 2024-07-12 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 21914562, 32901917, 35943828, Ito2013[abstract], 25356417, 37270787) |